GRIN Therapeutics (Series D)
Funding Details
- Awarder
- RSS - feeds.feedburner.com
- Date Award
- June 08, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $140,000,000
Company Info
- Traction
- Significant total near-term commitment of $115 million from Angelini Pharma, including a $65 million strategic equity investment and a $50 million upfront payment.
- Organizations Involved
- Angelini Pharma, Blackstone Life Sciences
- Company Description
- GRIN Therapeutics is a leader in the development of therapies to treat serious neurodevelopmental disorders, focusing on investigational drugs like radiprodil for rare genetic epilepsies.
- Market
- Neurodevelopmental disorders
- Location
- New York, NY, USA
- Coinvestors
- Angelini Pharma, Blackstone Life Sciences